139 related articles for article (PubMed ID: 29879894)
1. Evaluation of the Effect of α-L-Guluronic Acid (G2013) on COX-1, COX-2 Activity and Gene Expression for Introducing this Drug as a Novel NSAID with Immunomodulatory Property.
Mirshafiey A; Mortazavi-Jahromi SS; Taeb M; Cuzzocrea S; Esposito E
Recent Pat Inflamm Allergy Drug Discov; 2018; 12(2):162-168. PubMed ID: 29879894
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the oral administration of α-l-guluronic acid on COX-1 and COX-2 gene expression profile in ankylosing spondylitis patients.
Sadoughi A; Mansouri R; Nazeri S; Mirshafiey A
Drug Dev Res; 2021 Apr; 82(2):296-301. PubMed ID: 33140463
[TBL] [Abstract][Full Text] [Related]
3. Introduction of β-d-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property based on COX-1/COX-2 activity and gene expression.
Mirshafiey A; Taeb M; Mortazavi-Jahromi SS; Jafarnezhad-Ansariha F; Rehm BHA; Esposito E; Cuzzocrea S; Matsuo H
Pharmacol Rep; 2017 Oct; 69(5):1067-1072. PubMed ID: 28951072
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory Effect of G2013 (α-L-Guluronic Acid) on the TLR2 and TLR4 in Human Mononuclear Cells.
Sharifi L; Mohsenzadegan M; Aghamohammadi A; Rezaei N; Zavareh FT; Bokaie S; Moshiri M; Aghazadeh Z; Norouzbabaie Z; Azizi G; Mirshafiey A
Curr Drug Discov Technol; 2018; 15(2):123-131. PubMed ID: 28578651
[TBL] [Abstract][Full Text] [Related]
5. The Immunomodulatory Role of G2013 (α-L-Guluronic Acid) on the Expression of TLR2 and TLR4 in HT29 cell line.
Farhang H; Sharifi L; Dallal MMS; Moshiri M; Norouzbabaie Z; Bokaie S; Aletaha S; Zargar SJ; Mirshafiey A
Curr Drug Discov Technol; 2019; 16(1):91-95. PubMed ID: 29484999
[TBL] [Abstract][Full Text] [Related]
6. The effects of guluronic acid (G2013), a new emerging treatment, on inflammatory factors in nonalcoholic steatohepatitis patients under
Tahmasebi S; Neishaboori H; Jafari D; Faghihzadeh E; Esmaeilzadeh A; Mirshafiey A
Immunopharmacol Immunotoxicol; 2021 Oct; 43(5):562-570. PubMed ID: 34314306
[TBL] [Abstract][Full Text] [Related]
7. Effect of Guluronic Acid (G2013), As a New Anti-inflammatory Drug on Gene Expression of Pro-inflammatory and Anti-inflammatory Cytokines and Their Transcription Factors in Rheumatoid Arthritis Patients.
Bakhtiari T; Azarian S; Ghaderi A; Ahmadzadeh A; Mirshafiey A
Iran J Allergy Asthma Immunol; 2019 Nov; 18(6):639-648. PubMed ID: 32245307
[TBL] [Abstract][Full Text] [Related]
8. Anti-Diabetic and Angio-Protective Effect of Guluronic Acid (G2013) as a New Nonsteroidal Anti-Inflammatory Drug in the Experimental Model of Diabetes.
Mortazavi-Jahromi SS; Alizadeh S; Javanbakht MH; Mirshafiey A
Endocr Metab Immune Disord Drug Targets; 2020; 20(3):446-452. PubMed ID: 31622213
[TBL] [Abstract][Full Text] [Related]
9. An in vitro evaluation of anti-aging effect of guluronic acid (G2013) based on enzymatic oxidative stress gene expression using healthy individuals PBMCs.
Taeb M; Mortazavi-Jahromi SS; Jafarzadeh A; Mirzaei MR; Mirshafiey A
Biomed Pharmacother; 2017 Jun; 90():262-267. PubMed ID: 28364598
[TBL] [Abstract][Full Text] [Related]
10. Pivotal cytokines and their transcription factors are the targets of guluronic acid (G2013) for inhibiting the immunopathogenesis process of multiple sclerosis.
Hossein-Khannazer N; Shabani S; Farokhfar M; Azizi G; Asarzadegan F; Safarpour Lima B; Mirshafeiey A
Drug Dev Res; 2020 Jun; 81(4):511-516. PubMed ID: 32103523
[TBL] [Abstract][Full Text] [Related]
11. The effects of β-D-mannuronic acid (M2000), as a novel NSAID, on COX1 and COX2 activities and gene expression in ankylosing spondylitis patients and the murine monocyte/macrophage, J774 cell line.
Jafarnezhad-Ansariha F; Yekaninejad MS; Jamshidi AR; Mansouri R; Vojdanian M; Mahmoudi M; Fattahi MJ; Hashemi SN; Rehm BHA; Matsuo H; Esposito E; Cuzzocrea S; Mirshafiey A
Inflammopharmacology; 2018 Apr; 26(2):375-384. PubMed ID: 28819782
[TBL] [Abstract][Full Text] [Related]
12. G2013 modulates TLR4 signaling pathway in IRAK-1 and TARF-6 dependent and miR-146a independent manner.
Hajivalili M; Pourgholi F; Majidi J; Aghebati-Maleki L; Movassaghpour AA; Samadi Kafil H; Mirshafiey A; Yousefi M
Cell Mol Biol (Noisy-le-grand); 2016 Apr; 62(4):1-5. PubMed ID: 27188726
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of G2013 (α-L-guluronic acid) efficacy on PC-3 cells through inhibiting the expression of inflammatory factors.
Bagherian Z; Mirshafiey A; Mohsenzadegan M; Farajollahi MM
Clin Exp Pharmacol Physiol; 2022 Feb; 49(2):254-263. PubMed ID: 34699087
[TBL] [Abstract][Full Text] [Related]
14. The Evaluation of Safety Property and Apoptotic Efficacy of α-L-Guluronic Acid (G2013), as a Novel NSAID, Under
Hassani S; Afshari JT; Jafarnezhad-Ansariha F; Mirshafiey A
Recent Adv Inflamm Allergy Drug Discov; 2022; 15(1):9-15. PubMed ID: 34503439
[TBL] [Abstract][Full Text] [Related]
15. Effects of guluronic acid, as a new NSAID with immunomodulatory properties on IL-17, RORγt, IL-4 and GATA-3 gene expression in rheumatoid arthritis patients.
Khadem Azarian S; Jafarnezhad-Ansariha F; Nazeri S; Azizi G; Aghazadeh Z; Hosseinzadeh E; Mirshafiey A
Immunopharmacol Immunotoxicol; 2020 Feb; 42(1):22-27. PubMed ID: 31856612
[No Abstract] [Full Text] [Related]
16. Preclinical and pharmacotoxicology evaluation of α-l-guluronic acid (G2013) as a non-steroidal anti-inflammatory drug with immunomodulatory property.
Nazeri S; Khadem Azarian S; Fattahi MJ; Sedaghat R; Tofighi Zavareh F; Aghazadeh Z; Abdollahi M; Mirshafiey A
Immunopharmacol Immunotoxicol; 2017 Apr; 39(2):59-65. PubMed ID: 28145788
[TBL] [Abstract][Full Text] [Related]
17. Assessment of immunological profile in ankylosing spondylitis patients following a clinical trial with guluronic acid (G2013), as a new NSAID with immunomodulatory properties.
Mortazavi-Jahromi SS; Nazeri S; Jafarnezhad-Ansariha F; Oraei M; Mirshafiey A
Immunol Res; 2019 Feb; 67(1):108-115. PubMed ID: 30474833
[TBL] [Abstract][Full Text] [Related]
18. Effects of guluronic acid (G2013) on gene expression of TLR2, TLR4, MyD88, TNF-α and CD52 in multiple sclerosis under in vitro conditions.
Noorbakhsh SM; Razavi A; Moghadam NB; Saadat P; Hoseini M; Aghazadeh Z; Mobini M; Oraei M; Mirshafiey A
Immunopharmacol Immunotoxicol; 2019 Dec; 41(6):586-590. PubMed ID: 31594427
[No Abstract] [Full Text] [Related]
19. Effects of guluronic acid (G2013) on SHIP1, SOCS1 induction and related molecules in TLR4 signaling pathway.
Mortazavi-Jahromi SS; Farazmand A; Motamed N; Navabi SS; Mirshafiey A
Int Immunopharmacol; 2018 Feb; 55():323-329. PubMed ID: 29310108
[TBL] [Abstract][Full Text] [Related]
20. Anti-inflammatory drugs in the 21st century.
Rainsford KD
Subcell Biochem; 2007; 42():3-27. PubMed ID: 17612044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
